中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2014年
10期
901-904
,共4页
王旖旎%黄文秋%魏娜%曾祥宗%张嘉%王晶石%吴林%付丽%王昭
王旖旎%黃文鞦%魏娜%曾祥宗%張嘉%王晶石%吳林%付麗%王昭
왕의니%황문추%위나%증상종%장가%왕정석%오림%부려%왕소
淋巴组织细胞增多症,嗜血细胞性%挽救疗法%脂质体阿霉素%难治性
淋巴組織細胞增多癥,嗜血細胞性%輓救療法%脂質體阿黴素%難治性
림파조직세포증다증,기혈세포성%만구요법%지질체아매소%난치성
Lymphohistiocytosis,hemophagocytic%Salvage therapy%Liposomal doxorubicin%Refractory
目的 观察脂质体阿霉素联合依托泊苷和大剂量甲泼尼龙(DEP)方案挽救治疗成人难治性噬血细胞综合征(HLH)患者的有效性.方法 以41例难治性HLH患者为研究对象,采用DEP方案治疗2周和4周后,参照美国中西部协作组制订的标准进行疗效评价.结果 41例患者中,男28例,女13例,中位年龄31(18~62)岁.总反应率(ORR)为78.1%(32例),其中完全缓解(CR)率为29.3%(12例),部分缓解(PR)率为48.8%(20例).41例患者中有8例未找到引起HLH的原发病(CR 5例,PR2例);其余33例患者中原发性HLH 1例(CR 1例),淋巴瘤相关HLH 20例(CR 3例,PR 12例),EBV相关HLH 12例(CR 3例,PR 6例).对DEP方案无应答的9例患者均在开始挽救治疗后的2~4周内死亡;达到PR和CR的32例患者在诱导缓解后积极针对原发病治疗,包括化疗、异基因造血干细胞移植、脾脏切除等,其中20例患者病情持续缓解.结论 单臂研究结果提示,DEP方案可能是一种有效的用于成人难治性HLH患者的挽救治疗方案.
目的 觀察脂質體阿黴素聯閤依託泊苷和大劑量甲潑尼龍(DEP)方案輓救治療成人難治性噬血細胞綜閤徵(HLH)患者的有效性.方法 以41例難治性HLH患者為研究對象,採用DEP方案治療2週和4週後,參照美國中西部協作組製訂的標準進行療效評價.結果 41例患者中,男28例,女13例,中位年齡31(18~62)歲.總反應率(ORR)為78.1%(32例),其中完全緩解(CR)率為29.3%(12例),部分緩解(PR)率為48.8%(20例).41例患者中有8例未找到引起HLH的原髮病(CR 5例,PR2例);其餘33例患者中原髮性HLH 1例(CR 1例),淋巴瘤相關HLH 20例(CR 3例,PR 12例),EBV相關HLH 12例(CR 3例,PR 6例).對DEP方案無應答的9例患者均在開始輓救治療後的2~4週內死亡;達到PR和CR的32例患者在誘導緩解後積極針對原髮病治療,包括化療、異基因造血榦細胞移植、脾髒切除等,其中20例患者病情持續緩解.結論 單臂研究結果提示,DEP方案可能是一種有效的用于成人難治性HLH患者的輓救治療方案.
목적 관찰지질체아매소연합의탁박감화대제량갑발니룡(DEP)방안만구치료성인난치성서혈세포종합정(HLH)환자적유효성.방법 이41례난치성HLH환자위연구대상,채용DEP방안치료2주화4주후,삼조미국중서부협작조제정적표준진행료효평개.결과 41례환자중,남28례,녀13례,중위년령31(18~62)세.총반응솔(ORR)위78.1%(32례),기중완전완해(CR)솔위29.3%(12례),부분완해(PR)솔위48.8%(20례).41례환자중유8례미조도인기HLH적원발병(CR 5례,PR2례);기여33례환자중원발성HLH 1례(CR 1례),림파류상관HLH 20례(CR 3례,PR 12례),EBV상관HLH 12례(CR 3례,PR 6례).대DEP방안무응답적9례환자균재개시만구치료후적2~4주내사망;체도PR화CR적32례환자재유도완해후적겁침대원발병치료,포괄화료、이기인조혈간세포이식、비장절제등,기중20례환자병정지속완해.결론 단비연구결과제시,DEP방안가능시일충유효적용우성인난치성HLH환자적만구치료방안.
Objective To investigate the efficacy of liposomaldoxorubicin together with etoposide and high dose methylprednisolone (DEP) as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis (HLH).Methods Total 41 patients with refractory HLH were enrolled in this study.The efficacy of treatment with DEP regimen after 2 and 4 weeks were evaluated according to the United States Midwest Cooperative HLH Group.Results Of 41 refractory HLH patients,28 were males and 13 females.The median age was 31 (18-62) years old.The overall response rate (ORR) was 78.1% (32/41),including 12 patients (29.3%) achieved complete remission (CR) and 20 (48.8%) achieved partial remission (PR).The underlying disease of HLH were identified in 33 patients,including 1 case of primary HLH (CR),20 cases of lymphoma associated HLH and 12 cases of EBV associated HLH.There were still 8 cases with unknown underlying disease.The 9 patients who had no response to DEP died within 2 to 4 weeks after salvage therapy.Twenty of the 32 patients who achieved PR or CR survived to undergo subsequent chemotherapy,allogenic hematopoietic stem cell transplantation (allo-HSCT) or splenectomy.Conclusion The single-arm study suggested that DEP regimen appeared to be an effective salvage protocol for adult patients with refractory HLH.